NASDAQ:TARA Protara Therapeutics (TARA) Stock Price, News & Analysis $4.99 +0.02 (+0.40%) As of 10:35 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protara Therapeutics Stock (NASDAQ:TARA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Protara Therapeutics alerts:Sign Up Key Stats Today's Range$4.82▼$5.0550-Day Range$4.34▼$5.6652-Week Range$2.77▼$7.82Volume154,926 shsAverage Volume953,135 shsMarket Capitalization$280.44 millionP/E RatioN/ADividend YieldN/APrice Target$26.25Consensus RatingModerate Buy Company Overview Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease. Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells. By engaging OX40, PTX-35 aims to amplify anti-tumor T-cell responses and promote durable immunity against viral antigens. The company has also advanced preclinical vaccine programs targeting high-grade cervical dysplasia driven by HPV-16 and HPV-18, with the goal of reducing the need for surgical intervention. Headquartered in San Diego, California, Protara conducts early-stage clinical trials in North America and collaborates with academic research centers to explore combination regimens and next-generation immuno-oncology approaches. As a Nasdaq-listed company under the ticker TARA, Protara Therapeutics continues to build its pipeline through internal research and strategic partnerships aimed at addressing unmet needs in virus-associated oncology.AI Generated. May Contain Errors. Read More Protara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreTARA MarketRank™: Protara Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 405th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingProtara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialProtara Therapeutics has a consensus price target of $26.25, representing about 428.2% upside from its current price of $4.97.Amount of Analyst CoverageProtara Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.42) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protara Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protara Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtara Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Protara Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.79% of the float of Protara Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 9.57.Change versus previous monthShort interest in Protara Therapeutics has recently increased by 4.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtara Therapeutics does not currently pay a dividend.Dividend GrowthProtara Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.71 News SentimentProtara Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $124,989.00 in company stock.Percentage Held by Insiders7.60% of the stock of Protara Therapeutics is held by insiders.Percentage Held by Institutions38.13% of the stock of Protara Therapeutics is held by institutions.Read more about Protara Therapeutics' insider trading history. Receive TARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARA Stock News HeadlinesFoghorn Therapeutics (FHTX) Receives a Buy from H.C. WainwrightMay 21 at 6:02 PM | theglobeandmail.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 21 at 2:15 AM | americanbankingnews.comThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing confirmed. Goldman, Morgan Stanley, and 19 other banks have already carved up the allocation. But buried in those 277 pages is a detail most investors will miss. One small, publicly traded company is so critical to SpaceX's infrastructure that Musk can't scale without it - and the S-1 just confirmed it.May 22 at 1:00 AM | Behind the Markets (Ad)Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAMay 20 at 8:00 AM | globenewswire.comProtara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations TranscriptMay 19 at 11:02 PM | seekingalpha.comProtara’s cell therapy shows treatment durability in mid-stage NMIBC studyMay 19 at 1:28 PM | msn.comProtara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical ProgramMay 18, 2026 | quiverquant.comQProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026May 18, 2026 | globenewswire.comSee More Headlines TARA Stock Analysis - Frequently Asked Questions How have TARA shares performed this year? Protara Therapeutics' stock was trading at $5.33 at the start of the year. Since then, TARA shares have decreased by 6.8% and is now trading at $4.97. How were Protara Therapeutics' earnings last quarter? Protara Therapeutics, Inc. (NASDAQ:TARA) posted its earnings results on Wednesday, May, 13th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. When did Protara Therapeutics IPO? Protara Therapeutics (TARA) raised $79 million in an IPO on Wednesday, October 22nd 2014. The company issued 6,110,000 shares at $12.00-$14.00 per share. Who are Protara Therapeutics' major shareholders? Protara Therapeutics' top institutional shareholders include Janus Henderson Group PLC (9.27%), AIGH Capital Management LLC (2.95%), ADAR1 Capital Management LLC (1.67%) and Bank of America Corp DE (1.65%). Insiders that own company stock include Jacqueline Zummo, Jacqueline Zummo and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Protara Therapeutics? Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD). Company Calendar Last Earnings5/13/2026Today5/22/20267th Annual Oncology Innovation Summit: Insights for ASCO & EHA5/26/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 2 days ago, TARA's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TARA Previous SymbolNASDAQ:PRTO CIK1359931 Webwww.proteontherapeutics.com Phone(646) 844-0337Fax781-487-6729Employees30Year Founded2017Price Target and Rating Average Price Target for Protara Therapeutics$26.25 High Price Target$28.00 Low Price Target$24.00 Potential Upside/Downside+426.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.70% Return on Assets-36.02% Debt Debt-to-Equity RatioN/A Current Ratio15.69 Quick Ratio15.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.22 per share Price / Book1.55Miscellaneous Outstanding Shares56,200,000Free Float51,932,000Market Cap$280.44 million OptionableOptionable Beta1.53 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TARA) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plast...Smallcaps Daily | SponsoredNew wave of tech IPOs coming?Cerebras surged 68% on its first trading day, hitting a nearly $67 billion valuation - and investors are now a...Mode Mobile | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
